在一名接受静脉注射泊沙康唑且同时进行持续静脉-静脉血液滤过的重症患者中评估磺丁基醚-β-环糊精暴露情况。
Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration.
作者信息
Morris Amanda A, Mueller Scott W, Rower Joseph E, Washburn Taylor, Kiser Tyree H
机构信息
Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
出版信息
Antimicrob Agents Chemother. 2015 Oct;59(10):6653-6. doi: 10.1128/AAC.01493-15. Epub 2015 Aug 10.
Abstract
We present a 31-year-old female who had undergone an allogeneic bone marrow transplantation and who was started on intravenous posaconazole for pulmonary mycosis while undergoing continuous venovenous hemofiltration (CVVH). We performed steady-state pharmacokinetic evaluations for both posaconazole and sulfobutylether-β-cyclodextrin (SBECD). SBECD was effectively removed by CVVH, with observed exposure similar to that for patients with moderate renal impairment. Intravenous posaconazole at standard doses may be utilized in critically ill patients undergoing CVVH without significant risk of SBECD accumulation.
摘要
我们报告一名31岁女性，她接受了异基因骨髓移植，在进行持续静静脉血液滤过（CVVH）时因肺部真菌病开始静脉注射泊沙康唑。我们对泊沙康唑和磺丁基醚-β-环糊精（SBECD）进行了稳态药代动力学评估。CVVH有效地清除了SBECD，观察到的暴露情况与中度肾功能损害患者相似。在接受CVVH的重症患者中，可使用标准剂量的静脉注射泊沙康唑，而不会有SBECD蓄积的显著风险。
相似文献
1
Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration.
Antimicrob Agents Chemother. 2015 Oct;59(10):6653-6. doi: 10.1128/AAC.01493-15. Epub 2015 Aug 10.
2
Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
Crit Care. 2015 Feb 3;19(1):32. doi: 10.1186/s13054-015-0753-8.
3
Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
Ther Drug Monit. 2011 Aug;33(4):393-7. doi: 10.1097/FTD.0b013e3182205d93.
4
Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
J Clin Pharmacol. 2018 Jun;58(6):814-822. doi: 10.1002/jcph.1077. Epub 2018 Mar 26.
5
Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Int J Antimicrob Agents. 2015 Jan;45(1):41-5. doi: 10.1016/j.ijantimicag.2014.09.009. Epub 2014 Oct 18.
6
Phenytoin removal by continuous venovenous hemofiltration.
Ann Pharmacother. 2013 Sep;47(9):1218-22. doi: 10.1177/1060028013503131.
7
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Antimicrob Agents Chemother. 2010 Jun;54(6):2596-602. doi: 10.1128/AAC.01540-09. Epub 2010 Apr 5.
8
Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
Int J Antimicrob Agents. 2015 Jul;46(1):39-44. doi: 10.1016/j.ijantimicag.2015.02.014. Epub 2015 Mar 28.
9
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Clin Pharmacol Ther. 1999 Jan;65(1):50-7. doi: 10.1016/S0009-9236(99)70121-9.
10
A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration.
Int J Antimicrob Agents. 2018 Oct;52(4):506-509. doi: 10.1016/j.ijantimicag.2018.07.008. Epub 2018 Jul 19.
引用本文的文献
1
New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).
J Fungi (Basel). 2025 Jun 18;11(6):463. doi: 10.3390/jof11060463.
2
Extrapolating Antifungal Animal Data to Humans - Is it reliable?
Curr Fungal Infect Rep. 2020 Mar;14(1):50-62. doi: 10.1007/s12281-020-00370-x. Epub 2020 Jan 16.
3
Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Ann Clin Microbiol Antimicrob. 2019 Mar 20;18(1):13. doi: 10.1186/s12941-019-0311-3.
4
Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.
Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):139-157. doi: 10.1007/s13318-018-0513-7.
5
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12.
6
Scedosporium apiospermum and S. prolificans mixed disseminated infection in a lung transplant recipient: An unusual case of long-term survival with combined systemic and local antifungal therapy in intensive care unit.
Med Mycol Case Rep. 2016 Apr 30;11:53-6. doi: 10.1016/j.mmcr.2016.04.006. eCollection 2016 Mar.
本文引用的文献
1
Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
Crit Care. 2015 Feb 3;19(1):32. doi: 10.1186/s13054-015-0753-8.
2
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrob Agents Chemother. 2014 Jul;58(7):3610-7. doi: 10.1128/AAC.02686-13. Epub 2014 Apr 14.
3
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).
Haematologica. 2013 Apr;98(4):492-504. doi: 10.3324/haematol.2012.065110. Epub 2012 Sep 14.
4
Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.
Antimicrob Agents Chemother. 2011 Mar;55(3):1308-11. doi: 10.1128/AAC.01325-10. Epub 2010 Dec 28.
5
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Antimicrob Agents Chemother. 2010 Jun;54(6):2596-602. doi: 10.1128/AAC.01540-09. Epub 2010 Apr 5.
6
Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).
J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109.
7
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.
Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858.
8
Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Clin Drug Investig. 2008;28(7):409-20. doi: 10.2165/00044011-200828070-00002.
9
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258.
10
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Clin Infect Dis. 2007 Jan 1;44(1):2-12. doi: 10.1086/508774. Epub 2006 Nov 28.
Zotero 插件